Background. It is necessary to clarify the incidence of and risk factors for tuberculosis (TB) among solidorgan transplant (SOT) recipients as well as changes in the chronology, clinical presentation, and prognosis of the disease.
most of the studies describing risk factors have been retrospective, have included a small case series, and have lacked control patients without TB [5, [8] [9] [10] [11] .
The incidence of TB among SOT recipients depends on its incidence in the general population. Spain has a high TB incidence (18.9 cases per 10 5 inhabitants per year), a high prevalence of latent TB infection (125%) [12] , and great transplant activity [13] -that is, it has the necessary conditions to allow a prospective cohort study to include a sufficient number of cases for a reliable calculation of the incidence of TB and analysis of its risk factors.
The main aim of the present research was to study TB incidence and risk factors in a prospective cohort of SOT recipients. Case analysis allowed us to detect changes in the chronology, clinical presentation, and prognosis of the disease.
METHODS
The RESITRA (Spanish Network of Infection in Transplantation) cohort. RESITRA is a research network formed by 16 transplant centers in which all SOTs performed are prospectively included. Pretransplant, peritransplant, and follow-up data (from 0, 7, 14, 30, 60, 90, 180, 270, 360, 540, and 720 days after transplant) as well as infections and rejection episodes are prospectively recorded in an online database. Definitions have been published on the RESITRA Web site [14] . Data are extracted through managerial and statistical databases generated from the SQL Server (Microsoft) database, after completion of a validating process managed by the coordinator at each hospital. For the present study, we included all transplants in the prospective RESITRA cohort from September 2003 to the end of June 2006.
Tuberculin purified protein derivative (PPD) skin test. A PPD test was conducted at those centers for which it was included in their protocol. A positive PPD test result was defined as induration of у5 mm in diameter 48-72 h after the administration of 2 IU of strain RT-23 (equivalent to 5 IU of tuberculin PPD). When a patient was found to be positive by the PPD test, it was recommended that he or she undergo pretransplant chemoprophylaxis with isoniazid (300 mg/day for 6-9 months).
Case definitions. For TB diagnosis, definitions based on World Health Organization criteria were used [15, 16] . A patient was considered to have TB when Mycobacterium tuberculosis was isolated by culture or when M. tuberculosis DNA was isolated from a representative clinical sample, organ fluid, or tissue by polymerase chain reaction. Patients for whom TB was demonstrated histopathologically were also accepted. TB was classified as pulmonary (involvement of pulmonary parenchyma), extrapulmonary (involvement of other organs), or disseminated (involvement of at least 2 noncontiguous organs). Patients for whom TB was diagnosed on the basis of clinical or radiological suspicion (for whom the corresponding physician prescribed a specific treatment) were not accepted. Definitions were normalized and predefined for the cohort [14] .
The patient was considered to have been cured when symptoms disappeared (clinical cure) and when no M. tuberculosis was identified in the same type of clinical sample in which it had been identified previously (microbiological cure) after completion of an adequate treatment regimen. Likewise, death was considered to be related to TB when there was no clinical and/or microbiological cure at the time of death.
Calculation of TB incidence. The incidence of TB in the RESITRA cohort was calculated by dividing the number of patients with a diagnosis of TB by the time included in the cohort or the number of days at risk, expressed as the number of cases per 10 5 patients per year. Time of exposure to risk for each patient was estimated as the time from transplant to the development of TB, patient death, or the end of follow-up. On the basis of official incidence data from 2005 [12] , incidence in the general Spanish population was estimated to be 18.9 cases per 10 5 inhabitants per year. Immunosuppression and clinical management. Immunosuppression and clinical management were done according to the protocols of each center.
Variables analyzed as possible risk factors. As possible risk factors, we analyzed (1) pretransplant variables (recipient age, diabetes mellitus, chronic obstructive pulmonary disease, chronic renal failure, chronic hepatopathy, chronic hepatitis C virus infection, previous SOT, recipient's PPD test result, cytomegalovirus serological mismatch [seropositive donor/seronegative recipient], and HLA matching); (2) type of transplanted organ; and (3) posttransplant variables (use of cyclosporine, azathioprine, tacrolimus, sirolimus, muromonab-CD3, basiliximab, daclizumab, and everolimus as well as rejection episodes). We could not analyze the value of signs of residual TB lesions on pretransplant chest radiographs, because this variable was not included in the RESITRA database.
Statistical analysis. The global incidence of TB, the incidence of TB among SOT recipients, and the relative risk (RR) of TB were calculated along with 95% confidence intervals (CIs). A difference was considered to be statistically significant if the incidence of TB in the general Spanish population was found to be outside of the 95% CI of the incidence in the RESITRA cohort.
Continuous variables were expressed either as means and standard deviations (for variables with a normal distribution) or as medians and ranges (mostly for variables with a skewed distribution). Discrete variables were expressed as percentages.
Student's unpaired t test was used to compare continuous variables, the Mann-Whitney U test was used to compare continuous variables with a nonnormal distribution, and the x 2 or Fisher's exact test was used to compare proportions. All statistical tests were 2-tailed, and the threshold of statistical significance was established at . P ! .05 RRs were calculated for variables with statistically significant differences between patients with and those without TB. Cox regression was applied individually to each variable to obtain an RR in univariate analysis. Variables that were statistically significant ( ) in univariate analysis were introduced into P ! .05 a multivariate model by means of forward stepwise logistic regression, to identify independent risk factors for TB. In ad- dition, clinically relevant factors with that were consid-P ! .1 ered to be potential confounders (on the basis of experience and the existing literature) were forced into the multivariate model, with the aim of investigating their effect. Patients were censored at death or when they were lost to follow-up. SPSS statistical software, version 13.0 (SPSS), was used to perform calculations. Latent TB infection. In accordance with the protocols of each center and before transplant, the PPD test was done for 1775 patients (40.5%), and the result was positive for 338 (19.0%). Pretransplant chemoprophylaxis with isoniazid was performed for 147 (46.2%) of the 338 patients with a positive PPD test result. Table 2 describes PPD test data by type of transplant.
RESULTS

From
TB frequency and incidence. TB was diagnosed in 21 (0.48%) of the SOT recipients in the cohort (table 3) . This frequency represented an incidence of 512 cases per 10 5 patients per year (95% CI, 317-783), which was statistically significantly higher than that for the general Spanish population (18.9 cases per 10 5 inhabitants per year). TB incidence was statistically higher among SOT recipients than in the general population for all transplant types except the heart (255 cases per 10 5 patients per year; 95% CI, 6.5-1421)-for all other transplant types, the general population's incidence was within the 95% CI for the RESITRA cohort. The greatest TB incidence was observed for lung transplants (2072 cases per 10 5 patients per year; 95% CI, 565-5306), which was statistically higher than that observed for kidney transplants (RR, 3.87; 95% CI, 1.14-13.14). No statistically significant differences were observed between incidences for any of the other transplant types.
Although the incidence of TB among SOT recipients with a positive PPD test result (864 cases per 10 5 patients per year; 95% CI, 178-2526) was higher than the incidence among those with a negative result (190 cases per 10 5 patients per year; 95% CI, 39-554), the difference was not statistically significant (RR 4.21; 95% CI, 0.84-20.41).
Description of TB cases. The distribution of the 21 cases of TB was as follows: 8 cases among 1507 liver transplant recipients (0.53%), 7 among 2052 kidney transplant recipients (0.34%), 4 among 303 lung transplant recipients (1.32%), 1 among 404 heart transplant recipients (0.25%), and 1 among 122 kidney-pancreas transplant recipients (0.82%) (table 4). The median age of these patients was 59 years (range, 37-75 years).
For 15 (71.4%) of these 21 patients, no PPD test was performed, and none of them received prophylaxis with isoniazid. The PPD test result was positive for 3 (50.0%) of the 6 patients for whom it was performed. Only 1 of these 3 patients received prophylaxis.
TB appeared a median of 183 days after transplant (range, 28-499 days). Of the 21 cases, 20 (95.2%) appeared within the first posttransplant year. Most frequently, TB appeared after the third month (14 instances [66.7%]); in 7 instances (33.3%), TB appeared within the first 3 months.
Pulmonary TB was observed in 16 patients (76.2%; 2 cases had laryngeal involvement), extrapulmonary TB was observed in 3 patients (14.3%; 1 case of meningitis, 1 case of spondylitis, and 1 case of genitourinary tract TB), and disseminated TB was observed in 2 patients (9.5%). TB involved the pulmonary graft in all lung transplant recipients. No differences were observed in the time of appearance between pulmonary TB and extrapulmonary or disseminated TB. Treatment included isoniazid for all patients with TB. The most widely followed regimen was isoniazid, rifampicin or rifabutin, and pyrazinamide and/or ethambutol (for 2 months), followed by isoniazid and rifampicin or rifabutin (17 patients [81%]). For 3 patients, another drug was added for the first 2 months (ethambutol for 2 patients and moxifloxacin for 1). For 4 patients (19.0%), a rifamycin was not included in the therapeutic regimen; these patients were treated with isoniazid, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and either ethambutol or pyrazinamide. Ciprofloxacin was added for the first 2 months for 1 patient. The database did not enable us to analyze interactions between TB treatment and immunosuppressive drugs. Multidrug-resistant TB was not observed.
Crude mortality was 19.0% (4 cases); however, death was attributable to TB for only 2 patients (9.5%), 1 liver transplant recipient with meningitis (who was treated with 3 drugs, including rifampicin) and 1 kidney transplant recipient with disseminated TB (who was treated with 4 drugs, none of which were rifamycin).
TB risk factors. To study TB risk factors, we first performed a univariate analysis comparing patients who had TB with the remainder of the patients in the cohort (table 5) . Because of the paucity of events in the study cohort, we could not construct a multivariate logistic regression model that included only the major potential risk factors; instead, we performed an exploratory analysis of the major statistically significant variables obtained in univariate analysis, adjusting each variable for all other variables by constructing different logistic regression models that included a maximum of 2 variables. The potential risk factors that were consistently retained in the various models were recipient age (RR, 1.05; 95% CI, 1.0-1.1;
) and P p .021 lung transplant (RR, 5.6; 95% CI, 1.9-16.9;
). P p .002
DISCUSSION
Studies of TB after SOT usually report frequencies instead of incidences [17] , and the frequencies reported have been quite variable (1.2%-15%) [1] . Our study reports a TB frequency of 0.48%. A retrospective study conducted by GESITRA (Spanish Transplantation Infection Study Group) in the 1990s observed a frequency of 0.8% [3] . Other studies conducted in Spain have shown higher frequencies among both kidney [18] and lung [19, 20] transplant recipients. Our data reflect a slight decrease in the frequency of TB among SOT recipients. The obtained TB incidence (512 cases per 10 5 patients per year) was much higher than that observed in the general Spanish population (18.9 cases per 10 5 inhabitants per year; RR, 26.6), among recipients of allogeneic transplant of hematopoietic stem cells (135.6 cases per 10 5 transplant recipients per year) [17] , and among candidates for transplant (80 cases per 10 5 candidates per year) in our environment [21] . Therefore, patients undergoing SOT should be considered at high risk for the development of TB, although differences in incidence have been shown among different types of organ transplants. For organ transplants with a low incidence of TB, a greater sample size is required for differences to appear, as was demonstrated in the present study for heart transplant recipients.
TB incidence was particularly high among lung transplant recipients. Receipt of a pulmonary graft instead of another organ increases the risk of developing TB up to 5.6-fold. In our series, a lung transplant recipient had a 73.3-fold higher risk of developing TB than did a person from the general Spanish population. This problem was already known-Bravo et al. [19] reported a frequency of 6.4% among lung transplant recipients, and in our previous study [3] prevalence was 1.15%, similar to that observed here (1.32%). Risk factors that have been previously described in the literature are previous exposure to M. tuberculosis (positive PPD test result and/or signs of residual TB lesions on pretransplant chest radiographs), pretransplant clinical condition (dialysis, diabetes, cirrhosis, and hepatitis C virus infection), and the intensity of immunosuppression (use of antilymphocyte antibodies, type of basal immunosuppression, and intensification of immunosuppressive treatment as a result of rejection) [1, 5, 8, 10, 22, 23] . The demonstration that receipt of a pulmonary graft constitutes a risk factor for TB would be novel.
This reality should result in practical consequences for lung transplantation. TB should be considered early in the differential diagnosis of pulmonary infiltrates. For candidates with pulmonary infiltrates, the results of PPD testing and pretransplant chest radiography have limited value, because TB can appear through the reactivation of latent infection in the graft (especially for bipulmonary transplant recipients). It would be necessary to validate the profitability of new techniques-such as the quantification of interferon-g release in response to M. tuberculosis antigens (QuantiFERON-TB Gold test; Cellestis)-for the detection of latent infection in donors [24, 25] . It should also be emphasized that, of the 3 lung transplant recipients in the present study who developed TB, 2 had negative PPD test results before the transplant, and TB appeared in the pulmonary graft.
Here, recipient age was found to be a risk factor for TB, as has been observed in at least one other study [10] . The prevalence of latent TB infection has progressively decreased in Spain since the 1960s, likely as a result of an increase in Spain's sociohealth level [26, 27] ; this may explain why the risk of TB reactivation is higher in older SOT recipients, given that it mirrors the situation in the general population.
Current recommendations of chemoprophylaxis are based on a history of contact with M. tuberculosis (PPD test positivity, wrongly treated TB, or coresidence with a person with active TB) and/or the presence of signs of residual injuries on the recipient's chest radiograph [28] . These indications should be kept. The variables included in the RESITRA database hindered us in assessing whether the presence of signs of residual TB lesions on pretransplant chest radiographs constitutes a risk factor. The same problem has been faced by previous studies of risk factors [10] . The result of the pretransplant PPD test was positive for 19.0% of patients in the present study, a figure similar to that reported in our previous series (20%). Only 3 (0.9%) of 338 patients with a positive PPD test result developed TB, and one of them was a bipulmonary transplant recipient with graft TB whose PPD test result had limited value. PPD test positivity and isoniazid prophylaxis were not found to be risk factors for TB in the present study, but we cannot rule out the possibility that this finding was due to a lack of statistical power. The PPD test, despite being widely recommended, was conducted for only 40.6% of patients, whereas it had been performed for 59% of patients during the period 1980-1994. The PPD test was not performed for 15 (71.4%) of the 21 patients with a diagnosis of TB in the present study. Moreover, prophylaxis was prescribed for less than half of the patients with a positive PPD test result. It is necessary to insist on the advisability of performing the PPD test and administering prophylaxis when indicated. Because we cannot identify other risk factors (e.g., type of transplant and age), classic prevention strategies maintain all of their currency.
We did not find that the chronology of TB among SOT recipients is changing. Although in the present study 95% of cases were diagnosed within the first year after transplant during the period 2003-2006, compared with 61% during the period 1980-1994 in the preliminary study [3] , patient follow-up in the present study was far greater, thus favoring the inclusion of late forms of TB. Neither did we observe a change in the form in which the infection appeared-pulmonary forms predominated in both studies. Even though we ascertained a reduction in crude mortality (19.0% vs. 31%) and related mortality (9.5% vs. 20%) between the studies, the current TB mortality figure remains very high.
The use of rifampicin in the transplant context continues to provoke controversy, because it reduces immunosuppressor levels. Rifabutin has excellent efficacy with less cytochrome P450 induction, and it is an attractive alternative in the transplant population. Of the patients in our series, 81% were treated with a rifamycin. Some series have demonstrated that these drugs may be safe with rigorous control of immunosuppressor levels [29] , as has been acknowledged by European guidelines [30] , even though in certain cases they have increased the frequency of rejection and mortality [31] . In the present study, we did not observe higher crude mortality among patients who received a rifamycin (17.6% vs. 25%).
In short, we found the incidence of TB to be higher among SOT recipients than among the general population, in particular among lung transplant recipients and older SOT recipients. Nevertheless, our study of risk factors for TB has important limitations. We could not assess the value of signs of residual TB lesions on pretransplant chest radiographs, and a PPD test was not performed in many cases-although positivity was not related to a higher risk of TB among those for whom a PPD test was performed. Most patients with a positive PPD test result were treated with a rifamycin, and use of this class of drugs was not associated with higher mortality.
